TY - JOUR
T1 - Elevated cerebral glutamate and myo-inositol levels in cognitively normal middle-aged adults with metabolic syndrome
AU - Haley, Andreana P.
AU - Gonzales, Mitzi M.
AU - Tarumi, Takashi
AU - Miles, Steven C.
AU - Goudarzi, Katayoon
AU - Tanaka, Hirofumi
N1 - Funding Information:
Acknowledgements This work was funded by American Heart Association grant 09BGIA2060722 (APH) and the University of Texas at Austin (APH). The authors thank the UT Imaging Center staff for their help with the participants.
Funding Information:
Dr. Tanaka serves on the scientific advisory board for Endothelix, is funded by NIH grants #AG20966 and DA018431, and received research support from the American Heart Association and the Yoga Care Foundation.
Funding Information:
Conflict of interest disclosure Dr. Haley is funded by American Heart Association grant #09BGIA2060722 and received research support from the University of Texas at Austin and NINR Center Grant P30 NR005051.
PY - 2010/12
Y1 - 2010/12
N2 - Metabolic syndrome (MetS) is a cluster of risk factors associated with significant cardiovascular morbidity and mortality and diminished cognitive function. Given that the cerebral mechanisms mediating the relationship between peripheral metabolic dysfunction and cognitive impairment are unknown, we set out to examine the relationship between diagnosis of metabolic syndrome and cerebral metabolism. Thirteen participants with MetS (aged 48∈± ∈6 years) and 25 healthy adults (aged 51∈±∈6 years) underwent neuropsychological assessment, health screen and proton magnetic resonance spectroscopy (1H MRS) examining N-acetyl-aspartate (NAA), myo-inositol (mI), creatine (Cr), choline (Cho), and glutamate (Glu) concentrations in occipitoparietal grey matter. Cerebral metabolite ratios (NAA/Cr, Cho/Cr, mI/Cr, and Glu/Cr) of participants with MetS, defined by the International Diabetes Federation criteria, were compared with controls matched for age, education, cognition, and emotional function. There were no significant differences in global cognitive function, memory, language, and psychomotor performance between the groups. Diagnosis of MetS was associated with significantly higher mI/Cr (F(1,36)∈=∈5.02, p∈=∈0.031) and Glu/Cr ratio (F(1,36)∈=∈4.81, p∈=∈0.035). Even in cognitively normal adults, MetS is related to cerebral metabolic disturbances, a possible indication of early brain vulnerability. Longitudinal studies that begin in mid-life can help validate the use of 1H MRS markers as indicators of long-term cognitive outcomes.
AB - Metabolic syndrome (MetS) is a cluster of risk factors associated with significant cardiovascular morbidity and mortality and diminished cognitive function. Given that the cerebral mechanisms mediating the relationship between peripheral metabolic dysfunction and cognitive impairment are unknown, we set out to examine the relationship between diagnosis of metabolic syndrome and cerebral metabolism. Thirteen participants with MetS (aged 48∈± ∈6 years) and 25 healthy adults (aged 51∈±∈6 years) underwent neuropsychological assessment, health screen and proton magnetic resonance spectroscopy (1H MRS) examining N-acetyl-aspartate (NAA), myo-inositol (mI), creatine (Cr), choline (Cho), and glutamate (Glu) concentrations in occipitoparietal grey matter. Cerebral metabolite ratios (NAA/Cr, Cho/Cr, mI/Cr, and Glu/Cr) of participants with MetS, defined by the International Diabetes Federation criteria, were compared with controls matched for age, education, cognition, and emotional function. There were no significant differences in global cognitive function, memory, language, and psychomotor performance between the groups. Diagnosis of MetS was associated with significantly higher mI/Cr (F(1,36)∈=∈5.02, p∈=∈0.031) and Glu/Cr ratio (F(1,36)∈=∈4.81, p∈=∈0.035). Even in cognitively normal adults, MetS is related to cerebral metabolic disturbances, a possible indication of early brain vulnerability. Longitudinal studies that begin in mid-life can help validate the use of 1H MRS markers as indicators of long-term cognitive outcomes.
KW - Aging
KW - Cognition
KW - Glutamate
KW - H MRS
KW - Metabolic syndrome
KW - Myo-inositol
UR - http://www.scopus.com/inward/record.url?scp=78751587202&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=78751587202&partnerID=8YFLogxK
U2 - 10.1007/s11011-010-9221-y
DO - 10.1007/s11011-010-9221-y
M3 - Article
C2 - 21063759
AN - SCOPUS:78751587202
SN - 0885-7490
VL - 25
SP - 397
EP - 405
JO - Metabolic Brain Disease
JF - Metabolic Brain Disease
IS - 4
ER -